Ellen G. Feigal

3.5k total citations · 2 hit papers
43 papers, 2.8k citations indexed

About

Ellen G. Feigal is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Ellen G. Feigal has authored 43 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 14 papers in Pathology and Forensic Medicine and 9 papers in Genetics. Recurrent topics in Ellen G. Feigal's work include Lymphoma Diagnosis and Treatment (14 papers), Viral-associated cancers and disorders (13 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Ellen G. Feigal is often cited by papers focused on Lymphoma Diagnosis and Treatment (14 papers), Viral-associated cancers and disorders (13 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Ellen G. Feigal collaborates with scholars based in United States, United Kingdom and Canada. Ellen G. Feigal's co-authors include Phyllis A. Wingo, H. M. Rosenberg, Holly L. Howe, M. J. Thun, B. K. Edwards, Michael J. Thun, Brenda K. Edwards, Ahmedin Jemal, Rosemary Yancik and Lynn A. G. Ries and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Ellen G. Feigal

41 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Annual Report to the Nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden

2002 712 citations Brenda K. Edwards, Holly L. Howe et al. Cancer profile →
Annual Report to the Nation on the Status of Cancer (1973 Through 1998), Featuring Cancers With Recent Increasing Trends

2001 620 citations Holly L. Howe, Phyllis A. Wingo et al. JNCI Journal of the National Cancer Institute profile →

Peers

Countries citing papers authored by Ellen G. Feigal

Since Specialization

Citations

This map shows the geographic impact of Ellen G. Feigal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen G. Feigal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen G. Feigal more than expected).

Fields of papers citing papers by Ellen G. Feigal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen G. Feigal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen G. Feigal. The network helps show where Ellen G. Feigal may publish in the future.

Co-authorship network of co-authors of Ellen G. Feigal

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen G. Feigal. A scholar is included among the top collaborators of Ellen G. Feigal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen G. Feigal. Ellen G. Feigal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	At the end of the beginning: immunotherapies as living drugs 2019 ·Nature Immunology ·Ellen G. Feigal, Natalie DeWitt, (unknown), Carl C. Peck, David Stroncek	4
2	Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells 2014 ·Nature Biotechnology ·Peter W. Andrews, Joy Cavagnaro, Robert Deans, Ellen G. Feigal, (unknown), (unknown), Mahendra S. Rao, Marc Turner, (unknown), Shinya Yamanaka	44
3	Proceedings: International Regulatory Considerations on Development Pathways for Cell Therapies 2014 ·Stem Cells Translational Medicine ·Ellen G. Feigal, (unknown), Sowmya Viswanathan, Jiwen Zhang, Catherine Priest, Jonathan Pearce, Natalie Mount	14
4	Proceedings: Cell Therapies for Parkinson's Disease From Discovery to Clinic 2014 ·Stem Cells Translational Medicine ·Rosa Canet-Aviles, Geoffrey Lomax, Ellen G. Feigal, Catherine Priest	7
5	Developing Cellular Therapies for Retinal Degenerative Diseases 2014 ·Investigative Ophthalmology & Visual Science ·Kapil Bharti, Mahendra S. Rao, Sara Chandros Hull, David Stroncek, Brian P. Brooks, Ellen G. Feigal, Jan C. van Meurs, Christene A. Huang, Sheldon S. Miller	63
6	The Potential for Immunogenicity of Autologous Induced Pluripotent Stem Cell-derived Therapies 2013 ·Journal of Biological Chemistry ·(unknown), Sohel Talib, Ellen G. Feigal	49
7	Translation of Stem Cell Research: Points to Consider in Designing Preclinical Animal Studies 2012 ·Stem Cells Translational Medicine ·(unknown), Kevin J. Whittlesey, (unknown), Ellen G. Feigal	35
8	A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer 2012 ·Annals of Oncology ·Hedy L. Kindler, Donald Richards, Lawrence Garbo, Edward B. Garon, Joe Stephenson, Caio Rocha‐Lima, Howard Safran, (unknown), Darren M. Kocs, Francesco Galimi, Jesse McGreivy, Sarah Bray, Y. Hei, Ellen G. Feigal, Elwyn Loh, Charles S. Fuchs	157
9	A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC). 2010 ·Journal of Clinical Oncology ·Hedy L. Kindler, Donald Richards, John Stephenson, Lawrence Garbo, (unknown), (unknown), Jeffrey S. Wiezorek, Ellen G. Feigal, Sarah Bray, Christiane Fuchs	26
10	Capacity building for the clinical investigation of AIDS malignancy in East Africa 2005 ·Cancer Detection and Prevention ·Jackson Orem, (unknown), Cecily Banura, Edward Katongole‐Mbidde, John L. Johnson, Leona W. Ayers, Mahmoud Ghannoum, Pingfu Fu, Ellen G. Feigal, (unknown), Christopher C. Whalen, Michael M. Lederman, Scot C. Remick	10
11	Annual Report to the Nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden breakdown → 2002 ·Cancer ·Brenda K. Edwards, Holly L. Howe, Lynn A. G. Ries, Michael J. Thun, H. M. Rosenberg, Rosemary Yancik, Phyllis A. Wingo, Ahmedin Jemal, Ellen G. Feigal	712
12	Annual Report to the Nation on the Status of Cancer (1973 Through 1998), Featuring Cancers With Recent Increasing Trends breakdown → 2001 ·JNCI Journal of the National Cancer Institute ·Holly L. Howe, Phyllis A. Wingo, M. J. Thun, (unknown), H. M. Rosenberg, Ellen G. Feigal, B. K. Edwards	620
13	AIDS-associated malignancies: research perspectives 1999 ·Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ·Ellen G. Feigal	21
14	Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA 1999 ·Annals of Oncology ·Edward A. Sausville, Ellen G. Feigal	23
15	Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. 1998 ·Journal of Clinical Oncology ·Lauri Welles, M. Wayne Saville, Jill Lietzau, James M. Pluda, Kathleen M. Wyvill, Illinois Feuerstein, William D. Figg, Richard M. Lush, Jeanne Odom, Wyndham H. Wilson, (unknown), (unknown), Ellen G. Feigal, D Tuck, Seth M. Steinberg, S Broder, Robert Yarchoan	127
16	The challenge of designing clinical trials for AIDS-related Kaposi's sarcoma. 1998 ·PubMed ·Richard F. Little, James M. Pluda, Ellen G. Feigal, Robert Yarchoan	5
17	Favored use of immunoglobulin V(H)4 Genes in AIDS-associated B-cell lymphoma 1996 ·Blood ·Alberto Bessudo, (unknown), Todd A. Johnson, (unknown), Ellen G. Feigal, T J Kipps	27
18	Human T Cell Leukemia Virus (HTLV-I/II) Serodiagnostic Testing: Disparate Results among a Cohort of Intravenous Drug Users 1993 ·AIDS Research and Human Retroviruses ·David M. Aboulafia, Ellen G. Feigal, (unknown), (unknown), William A. Blattner, (unknown), Dennis J. Slamon	5
19	Neoadjuvant therapy in cancer treatment 1993 ·Cancer ·Edward L. Trimble, Richard S. Ungerleider, (unknown), Richard Kaplan, Ellen G. Feigal, Malcolm A. Smith, (unknown), Michael Friedman	43
20	Human T Cell Lymphotropic Virus Types I and II in Intravenous Drug Users in San Francisco: Risk Factors Associated with Seropositivity 1991 ·The Journal of Infectious Diseases ·Ellen G. Feigal, (unknown), K M Vranizan, Peter Bacchetti, Richard E. Chaisson, J. E. Drummond, William A. Blattner, Michael S. McGrath, John S. Greenspan, Andrew R. Moss	55

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact